Drugs / Microlyvaq™
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 0 | NCT07285434 Comparator | Feb 2026 → Feb 2028 expected | non-small cell lung carcinoma, squamous cell lung carcinoma | Biogenea Pharmaceuticals Ltd. | Enrolling by invitation | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Microlyvaq | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07285434 ↗ |
| Modality | Vaccine | “personalized multi-epitope peptide vaccine” NCT07285434 ↗ |
| Route | Subcutaneous | “The vaccine is administered by subcutaneous or intradermal injection” NCT07285434 ↗ |